EUVIMEDEUVIMED entdecken
Crossref

The Effective Inhibitory Concentration of Interferon-β Correlates with Infectivity and Replication Fitness of SARS-CoV-2 Variants

Janmejay Singh, Anbalagan Anantharaj, Parveen Kumar, Rajesh Pandey, Anil Kumar Pandey, Guruprasad R Medigeshi iD

Journal of Interferon & Cytokine Research · 2024

DOI: 10.1089/jir.2024.0016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Interferon & Cytokine Research, 2024. Verfasst von Janmejay Singh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Bioassay Laboratory, Translational Health Science and Technology Institute, Faridabad, Haryana, India. Hauptthemen laut MEDLINE: SARS-CoV-2, Interferon-beta, Virus Replication, COVID-19. Die Arbeit nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

India saw a spike in COVID-19 cases in early 2023, and this wave of infection was attributed to XBB sublineages of SARS-CoV-2 Omicron variant. The impact of XBB wave was significantly shorter with low burden of severe cases or hospitalization as compared with previous SARS-CoV-2 variants of concern. Although a combination of old and new mutations in the spike region of XBB.1.16 variant led to a drastic reduction in the ability of antibodies from prior immunity to neutralize this virus, additional nonspike mutations suggested a possible change in its ability to suppress innate immune responses. In this study, we tested the sensitivity of Delta, BA.2.75, and XBB.1.16 variants to interferon-β (IFN-β) treatment and found that XBB.1.16 variant was most sensitive to IFN-β. We next tested the ability of serum antibodies from healthy individuals to neutralize XBB.1.16. We showed that most of the individuals with hybrid immunity maintained a low but significant level of neutralizing antibodies to XBB.1.16 variant. Therefore, our observations indicated that both hybrid immunity because of natural infection and enhanced sensitivity to IFNs may have contributed to the low impact of XBB.1.16 infections in India.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Interferon-betaVirus ReplicationCOVID-19Antibodies, NeutralizingHumansMutationAntibodies, ViralIndiaSpike Glycoprotein, CoronavirusAntiviral AgentsChlorocebus aethiopsVero Cells

Stichwörter der Autor:innen

SARS-CoV-2antibodiesinterferoninterferon-stimulated genesneutralization

Substanzen

Interferon-betaAntibodies, NeutralizingAntibodies, ViralSpike Glycoprotein, CoronavirusAntiviral Agents

Autor:innen und Institutionen

  • Bioassay Laboratory, Translational Health Science and Technology Institute, Faridabad, Haryana, India.
  • INtegrative GENomics of HOst-PathogEn (INGEN-HOPE) Laboratory, CSIR-Institute of Genomics and Integrative Biology, Delhi, India.
  • Academic Block, Employees State Insurance Corporation Medical College and Hospital, Faridabad, Haryana, India.
  • Department of Biology, Indian Institute of Science Education and Research, Tirupati, Andhra Pradesh, India.

ORCID-Profile: Guruprasad R Medigeshi

Zitieren

APA

Singh, J., Anantharaj, A., Kumar, P., Pandey, R., Pandey, A. K., & Medigeshi, G. R. (2024). The Effective Inhibitory Concentration of Interferon-β Correlates with Infectivity and Replication Fitness of SARS-CoV-2 Variants. Journal of Interferon & Cytokine Research. https://doi.org/10.1089/jir.2024.0016

Vancouver

Singh J, Anantharaj A, Kumar P, Pandey R, Pandey AK, Medigeshi GR. The Effective Inhibitory Concentration of Interferon-β Correlates with Infectivity and Replication Fitness of SARS-CoV-2 Variants. Journal of Interferon & Cytokine Research. 2024. doi:10.1089/jir.2024.0016

BibTeX
@article{Singh2024,
  author = {Singh, Janmejay and Anantharaj, Anbalagan and Kumar, Parveen and Pandey, Rajesh and Pandey, Anil Kumar and Medigeshi, Guruprasad R},
  title = {The Effective Inhibitory Concentration of Interferon-β Correlates with Infectivity and Replication Fitness of SARS-CoV-2 Variants},
  journal = {Journal of Interferon & Cytokine Research},
  year = {2024},
  doi = {10.1089/jir.2024.0016}
}
Kostenlos starten →